Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Repeated vaccination effective in protecting against severe influenza

09 Jan 2018

Repeated influenza vaccination is effective in preventing severe vs nonsevere influenza infections in elderly adults, a recent multicentre, case-control study has shown.

The study included 130 and 598 patients with severe and nonsevere influenza, who were then matched to 333 and 1,493 controls, respectively.

Vaccination in the current season and at least one of the three previous seasons led to significantly lower odds of severe disease (adjusted odds ratio [OR], 0.45; 95 percent CI, 0.26–0.76; p=0.003), intensive care unit (ICU) admission (adjusted OR, 0.35; 0.17–0.70; p=0.003) and death (adjusted OR, 0.44; 0.23–0.86; p=0.02).

In comparison, those who were only vaccinated in the current season did not reduce risks of severe disease (adjusted OR, 2.22; 0.89–5.51; p=0.09) and ICU admissions (adjusted OR, 1.14; 0.34–3.87; p=0.8), and had significantly higher risk of death (adjusted OR, 3.35; 1.06–10.58; p=0.04).

Moreover, those who were unvaccinated were admitted to the ICU more frequently (16 vs 6 percent; p<0.001) compared with those who were vaccinated. Mortality rates within the first 30 days after admission were also higher in unvaccinated participants (14 vs 9 percent; p=0.04).

In terms of hospital admissions, those who were vaccinated in the current season and in any of the three previous seasons were less likely to be admitted to the hospital for nonsevere influenza (31 percent effectiveness). Effectiveness estimates were higher for preventing ICU admission (74 percent) and death (70 percent).

Furthermore, those who were vaccinated in the current season only were not significantly protected against severe influenza.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.